| |
Ambiq® (ambiq.com), a technology leader in ultra-low-power solutions for edge AI, announced a strategic partnership with CardioMedive, an award-winning health technology innovator, to revolutionize cardiovascular care with the Medive an advanced modular health monitoring platform powered by the Apollo510.
Breakthrough Technical Innovations
Ultra-low power Apollo510 MCU employs the Subthreshold Power Optimized Technology (SPOT®) platform to deliver unparalleled energy efficiency for high-performance edge AI
Modular plug-and-play scalable architecture tailored to patient needs, no more managing separate devices. It integrates clinical-grade 1 lead multi-parameter patch, 3/5/12-lead ECGs, blood pressure, SpO2, temperature, respiration, digital stethoscope, and comprehensive remote examination capabilities
Multi-week battery life ensures continuous health data capture in a lightweight, unobtrusive design
Dual SDIO interfaces handle high-throughput Wi-Fi and eMMC storage simultaneously, enabling seamless connectivity without performance comprises
Transforming Healthcare Access Through Edge AI
The Medive uses AI-driven analytics to deliver hospital-grade cardiovascular insights in diverse settings, from clinics to patients’ homes. By leveraging the Apollo510’s powerful edge computing capabilities for on-device inferencing, Medive enables immediate anomaly detection, real-time patient alerts, and predictive insights, drastically reducing the latency issues associated with cloud-based communications. The Apollo510 dual SDIO architecture enables Medive to run high-throughput Wi-Fi and eMMC Storage simultaneously, delivering fast performance and seamless connectivity with zero trade-offs. The Medive was selected as the “Medical Innovation of the Year” winner by the Romanian Healthcare Awards for advancing remote cardiovascular patient monitoring.
“CardioMedive is transforming all phases of the patient’s journey for both in-home and hospital care,” says Fumihide Esaka, CEO of Ambiq. “We are proud to power such an important digital health innovation that makes effective prevention, diagnosis, and disease management more accessible using our ultra-low power solutions.”
Ion Mocanu, CEO & Co-founder of CardioMedive, added,“Our partnership with Ambiq has been instrumental in creating a truly groundbreaking platform that addresses critical healthcare challenges. The Apollo510’s exceptional processing power, peripherals and energy efficiency have enabled us to design a solution that not only meets today’s needs but is future proofed for tomorrow’s healthcare innovations.”
Comprehensive Health Monitoring
Patients using Medive can monitor a wide range of vital health metrics, including ECG, blood pressure, and SpO₂, while also conducting specialized examinations using modules for stethoscope exams, spirometry, otoscopy, thermal imaging for diabetes-related complications, breast cancer screening, and more.
Availability
CardioMedive is on track for commercial launch in Q3 2026, beginning in Europe and the U.K., with phased expansion to the U.S., Canada, and Asia-Pacific markets in 2027.
About Ambiq
Our mission is to enable intelligence (artificial intelligence (AI) and beyond) everywhere by delivering the lowest power semiconductor solutions. We enable our customers to deliver artificial intelligence compute at the edge where power consumption challenges are the most profound. Our technology innovations, built on the patented and proprietary subthreshold power optimized technology (SPOT), fundamentally deliver a multi-fold improvement in power consumption over traditional semiconductor designs. We’ve powered over 270 million devices today.
About CardioMedive
CardioMedive (cardiomedive.eu) is a health technology company redefining how cardiovascular care is delivered through a modular, AI-enabled monitoring platform that adapts to patients’ needs at home, in clinics, or anywhere in between. Combining medical-grade accuracy with user-friendly design, CardioMedive empowers providers, patients, and digital health platforms to detect, manage, and respond to heart health anomalies.
|
cwan[.]ambiq.com 
